Clinical Trials Logo

Clinical Trial Summary

To determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.


Clinical Trial Description

The purpose of this project is to determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, and reinforcement in smokers with different levels of dependence. Participants will have an Adaptation Session followed by 4 Test Days. The Adaptation Session will familiarize the participants with study procedures. In each Test Day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. Participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. This will be followed by 4 Choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline to be administered by the research staff. Reinforcement will be assessed with the percentage of nicotine choices during the Choice trials. The discrimination is the percentage of correctly identified nicotine and saline infusions. Rewarding effects will be assessed with the "Pleasurable Effects" composite score of the Drug Effects Questionnaire (DEQ). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06096714
Study type Interventional
Source Yale University
Contact Stacy Minnix, B.S
Phone 203-932-5711
Email stacy.minnix@yale.edu
Status Recruiting
Phase Early Phase 1
Start date February 27, 2024
Completion date January 30, 2027

See also
  Status Clinical Trial Phase
Completed NCT01228175 - Effectiveness of Varenicline: Testing Individual Differences Phase 4